The START Trial - A clinical research Study of Thymoglobulin to Arrest Type 1 Diabetes

START - a clinical research study of thymoglobulin to arrest type 1 diabetes

START | learning
Recently diagnosed with type 1 diabetes? It’s not all bad news. It is likely that you still have millions of insulin-producing beta cells still at work.
Read more.

START | the trial
Your beta cells are precious. START aims to prevent further destruction of the ones that remain at the time of diagnosis to try to stop your diabetes from developing further.
Read more.

START | participating
START is for individuals 12-35 years old (**18-35 only at present**) who have been diagnosed with type 1 diabetes within the past 3 months. Find out if you or your child may be eligible.
Read more.

Find a clinical site

START is taking place at clinical centers in the following cities. Click on the one nearest you for contact information. Additional clinical centers will be open soon.

San Francisco	Los Angeles	San Diego	Denver
Minneapolis	Kansas City	Philadelphia

	START is being conducted by the Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, with support from the NIDDK and JDRF. Additional in-kind support has been generously provided by LifeScan, Inc.